Session » Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2780

A Modification of the Psoriatic Arthritis Disease Activity Score (mPASDAS) Using SF-12 As a Measure of Quality of Life

9:00AM-11:00AM: Abstract Number: 2724

A Prospective Study of Ankylosing Spondylitis in China with Smart Management System for Spondyloarthritis: Study Design and Baseline Characteristics of the 449 Recruited Patients

9:00AM-11:00AM: Abstract Number: 2745

Adult Axial Spondyloarthritis Screening and Referral Practices Amongst Primary Care Physicians, Physiotherapists, Chiropractors and Nurse Practitioners: Results from a Qualitative Study

9:00AM-11:00AM: Abstract Number: 2760

Assessment of Inflammatory Back Pain and Axial Spondyloarthritis in Brazil

9:00AM-11:00AM: Abstract Number: 2773

Assessment of the Static and Dynamic Balances in Psoriatic Arthritis (PsA) and Their Relations with Clinical, Radiological and Functional Parameters of Feet

9:00AM-11:00AM: Abstract Number: 2772

Back Pain in Psoriatic Arthritis: Defining Prevalence, Characteristics and Performance of the Different Inflammatory Back Pain Criteria in a Psoriatic Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 2779

Better Health-Related Quality of Life and Work Capacity in Patients Achieving Inactive Disease and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2740

Cam Type Femoroacetabular Impingement Morphology Is More Frequent in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2753

Characteristic and Outcomes of Psoriatic Arthritis Patients with Hyperuricemia, Whether We Should Treat or Not?

9:00AM-11:00AM: Abstract Number: 2749

Characteristics of Ankylosing Spondylitis Patients with Primary and Secondary Lack of Efficacy to TNF-Inhibitor Treatments

9:00AM-11:00AM: Abstract Number: 2776

Comparability of Patients Classified As Non-Radiographic Axial Spondyloarthritis By the Imaging Vs Clinical Arms of the ASAS Criteria

9:00AM-11:00AM: Abstract Number: 2746

Comparing Prevalence of Comorbidities in Patients with Psoriatic Arthritis By Biologic Therapy

9:00AM-11:00AM: Abstract Number: 2755

Comparison of Clinical Profile of Geriatric and Non-Geriatric Ankylosing Spondylitis (AS) Patients

9:00AM-11:00AM: Abstract Number: 2750

Concordance Between Patient and Physician Global Assessment of the Disease in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2775

Conductive Hearing Loss Is Common in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2747

Dapsa-28 May be Used Instead of Dapsa-66/68 in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2752

Depression Is Associated with Worse Outcomes in Axial Spondyloarthropathy Population

9:00AM-11:00AM: Abstract Number: 2728

Discontinuation of Biologic Therapy in Patients with Ankylosing Spondylitis—Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 2743

Do Specific Entheseal Points in Spa Patients Impact Patient Reported Outcomes? Implications for Clinical Practice

9:00AM-11:00AM: Abstract Number: 2736

Do Validated Tools of Disease Activity in Ankylosing Spondylitis Measure Fibromyalgia Pain?

9:00AM-11:00AM: Abstract Number: 2769

Does Gender Make a Difference in “Composite Psoriatic Disease Activity Index (CPDAI)” in Patients with Psoriatic Arthritis?

9:00AM-11:00AM: Abstract Number: 2725

Elevated Disease Activity in Disease-Related Spondyloarthritis Despite Use of Tumor Necrosis Factor Inhibitor Therapies

9:00AM-11:00AM: Abstract Number: 2727

Evaluating Psoriatic Arthritis and Psoriasis Skin Lesions: Ultrasound As a Complementary Measure

9:00AM-11:00AM: Abstract Number: 2722

Evolution over Thirty Years of the Profile of Inpatients with Reactive Arthritis in a Tertiary Rheumatology Unit

9:00AM-11:00AM: Abstract Number: 2733

Fatigue, Pain and Patient Global Assessment Fluctuate Substantially in Spondyloarthropathy Patients with Stable Disease According to Basdai

9:00AM-11:00AM: Abstract Number: 2774

Framingham Risk Score Discriminates Coronary Atherosclerosis in Psoriatic Arthritis Patient Better Than Other Cardiovascular Scores Do

9:00AM-11:00AM: Abstract Number: 2751

Gender and Disease Duration Are Associated with Extra-Articular Manifestations in Axial Spondyloarthropathy

9:00AM-11:00AM: Abstract Number: 2756

Gender Differences in Body Composition with Dual-Energy X-Ray Absorptiometry in TNF-α Blocker Naive Ankylosing Spondylitis Patients

9:00AM-11:00AM: Abstract Number: 2771

Higher Incident Rates of Comorbidities in Patients with Psoriatic Arthritis (PsA) Compared to Controls

9:00AM-11:00AM: Abstract Number: 2742

How Are Enthesitis, Dactylitis and Nail Involvement Measured and Reported in Recent Clinical Trials of Psoriatic Arthritis (PsA)? a Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 2731

Illness Perceptions and Health-Related Quality of Life in Patients with Axial Spondyloarthritis and Other Forms of Chronic Back Pain in the Spondyloarthritis Caught Early (SPACE)-Cohort

9:00AM-11:00AM: Abstract Number: 2730

Impact of Disease Flare Perception on Work Productivity and Treatment Satisfaction in Patients with Psoriatic Arthritis in Real World Setting

9:00AM-11:00AM: Abstract Number: 2721

Impact of Nail Psoriasis on Clinical Presentation of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 2734

Is Disease Activity Associated with Negative Illness Perceptions in Early Axial Spondyloarthritis Patients in the Spondyloarthritis Caught Early (SPACE)-Cohort?

9:00AM-11:00AM: Abstract Number: 2777

Is There a Difference in Clinical Features and Burden of Disease in Patients with Axial Spondyloarthritis with and without Extra-Articular Manifestations?

9:00AM-11:00AM: Abstract Number: 2778

Is There Any Gender Specific Difference in Discriminative Value of Inflammatory Back Pain Criteria?

9:00AM-11:00AM: Abstract Number: 2732

Meaningful Involvement of Patients in the Development of a Core Outcome Set for Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2767

Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Evaluation of Modified Minimal Disease Activity upon Elimination of Each Component

9:00AM-11:00AM: Abstract Number: 2758

Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria Are More Prevalent Among Responders?

9:00AM-11:00AM: Abstract Number: 2763

New Treatment Option for SAPHO?

9:00AM-11:00AM: Abstract Number: 2737

Posttraumatic Stress Disorder and Correlates of Disease Activity Among Veterans with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2765

Practicing What We Preach? Do Psoriatic Arthritis Patients Treated at an Academic Medical Center Meet Caspar Criteria?

9:00AM-11:00AM: Abstract Number: 2759

Prevalence of Comorbidities and Risk Factors of Spondyloarthritis in Latin America: A Comparative Study with the General Population: Data from the Multinational ASAS-Comospa Study

9:00AM-11:00AM: Abstract Number: 2748

Prevalence of Comorbidities in Patients with Axial Spondyloarthritis and Its Association with Aspects of the Disease

9:00AM-11:00AM: Abstract Number: 2726

Prevalence of HLA-B27 in the Normal Population and Patients with Axial Spondyloarthritis in Saudi Arabia

9:00AM-11:00AM: Abstract Number: 2768

Prevalence of Obesity in Patients with Psoriatic Arthritis and Its Impact on the Severity of the Disease

9:00AM-11:00AM: Abstract Number: 2770

Psoriatic Arthritis Limits Patients’ Abilities to Undertake Activities Crucial for Normal Daily Life and Impacts Happiness, Results from a Multinational Real-World Sample

9:00AM-11:00AM: Abstract Number: 2735

Regional Variability of Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: An Analysis from a Prospective, Observational Registry

9:00AM-11:00AM: Abstract Number: 2741

Reliability and Construct Validity of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire – Independent Validation Study in a UK Cohort

9:00AM-11:00AM: Abstract Number: 2757

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 104 Weeks Results from a Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 2754

Self-Reported Physical Activity Questionnaire in Axial Spondyloarthritis: Modification of the Squash

9:00AM-11:00AM: Abstract Number: 2761

Sleep Disturbance in Psoriatic Disease: Prevalence and Associated Factors

9:00AM-11:00AM: Abstract Number: 2762

Smoking and Severity of Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2739

Subclinical Ungueal Distrophy in Patients with Psoriasis without Joint Involvement: Is There Any Role for Nail Ultrasound?

9:00AM-11:00AM: Abstract Number: 2723

The Co-Occurrence of Axial Spondyloarthritis and Fibromyalgia: A National Register-Based Study

9:00AM-11:00AM: Abstract Number: 2738

The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2766

The Predictive Value of Patient’s and Evaluator’s Global Assessment and Tender and Swollen Joint Count Differences on Treatment Efficacy in Psoriatic Arthritis: Data from a Longitudinal Multicenter Study

9:00AM-11:00AM: Abstract Number: 2729

Treatment Patterns, Unmet Need, and Impact of Psoriatic Arthritis on Patient-Reported Outcomes in the United States

9:00AM-11:00AM: Abstract Number: 2764

Unhappiness Is Related to Worse Outcomes for Patients with Ankylosing Spondylitis and Increased Impairment in Daily Life Activities, Results from a Multinational Real-World Sample

9:00AM-11:00AM: Abstract Number: 2744

Utilization of the Psoriasis Epidemiology Screening Tool (PEST) Questionnaire to Detect Psoriatic Arthritis in Clinical Practice: Data from the Validation of Psoriatic Arthritis Screening Tool for Korean Psoriasis Patients (VALOR) Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].